Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Total net revenue		$ 116,275	$ 97,459	$ 223,717	$ 182,791
Total cost of revenue	[1]	73,648	56,628	141,566	106,557
Research and development	[2]	14,697	11,956	29,079	24,104
Products
Total net revenue	[3]	60,721	41,805	113,480	73,063
Total cost of revenue		35,520	23,102	67,029	41,528
Services
Total net revenue	[4]	55,554	55,654	110,237	109,728
Total cost of revenue		38,128	33,526	74,537	65,029
Revenue from Joint Venture
Total cost of revenue		6,203	2,757	14,248	4,701
Research and development		415	430	994	430
Revenue from Joint Venture | Products
Total net revenue		8,816	1,446	14,735	4,320
Revenue from Joint Venture | Services
Total net revenue		$ 2,679	$ 3,186	$ 5,494	$ 5,262

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $6,203 and $14,248 for the three and six months ended December 31, 2021 and $2,757 and $4,701 for the three and six months ended December 31, 2020, respectively.

[2] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $415 and $994 for the three and six months ended December 31, 2021 and $430 for the three and six months ended December 31, 2020.

[3] Includes sales to the China joint venture, an equity method investment of $8,816 and $14,735 for the three and six months ended December 31, 2021 and $1,446 and $4,320 for the three and six months ended December 31, 2020, respectively. See Note 14.

[4] Includes sales to the China joint venture, an equity method investment of $2,679 and $5,494 for the three and six months ended December 31, 2021 and $3,186 and $5,262 for the three and six months ended December 31, 2020, respectively. See Note 14.